Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

Tumour mutational burden (TMB) has emerged as a promising biomarker to predict immune checkpoint inhibitors (ICIs) response in advanced solid cancers. However, harmonisation of TMB reporting by targeted gene panels is lacking, especially in metastatic tumour samples. To address this issue, we used d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mankor, Joanne M., Paats, Marthe S., Groenendijk, Floris H., Roepman, Paul, Dinjens, Winand N. M., Dubbink, Hendrikus J., Sleijfer, Stefan, Cuppen, Edwin, Lolkema, Martijn P. J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109082/
https://www.ncbi.nlm.nih.gov/pubmed/32094484
http://dx.doi.org/10.1038/s41416-020-0762-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109082/
https://www.ncbi.nlm.nih.gov/pubmed/32094484
http://dx.doi.org/10.1038/s41416-020-0762-5

Ejemplares similares